In phase III trials, Crizotinib has shown a striking activity in NSCLC patients harboring the rare EML4-ALK translocation, leading to expression of a constitutively active ALK kinase (Kwak et al., 2010). Here, ALK is linked to non-small cell lung carcinoma.